The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression
Authors
Keywords
-
Journal
NEUROPHARMACOLOGY
Volume -, Issue -, Pages 109299
Publisher
Elsevier BV
Online
2022-11-03
DOI
10.1016/j.neuropharm.2022.109299
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Effectiveness of Repeated Intravenous Ketamine on Subjective and Objective Psychosocial Function in Patients with Treatment-Resistant Depression and Suicidal Ideation
- (2022) Yanling Zhou et al. JOURNAL OF AFFECTIVE DISORDERS
- The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis
- (2022) Muhammad Youshay Jawad et al. Expert Opinion On Drug Safety
- Predictors of suicidal ideation trajectories in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study
- (2022) Bartholt Bloomfield-Clagett et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis
- (2022) Yazen Alnefeesi et al. JOURNAL OF PSYCHIATRIC RESEARCH
- The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits
- (2022) Danica Nogo et al. PSYCHOPHARMACOLOGY
- Psychedelic drugs take on depression
- (2022) Cassandra Willyard NATURE
- Arketamine, a new rapid-acting antidepressant: A historical review and future directions
- (2022) Ji-chun Zhang et al. NEUROPHARMACOLOGY
- Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
- (2021) Yan Wei et al. MOLECULAR PSYCHIATRY
- Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study
- (2021) Nagahide Takahashi et al. BMC Psychiatry
- Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review
- (2021) Jason Ng et al. JOURNAL OF AFFECTIVE DISORDERS
- The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality
- (2021) Yanling Zhou et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Pragmatic Precision Psychiatry—A New Direction for Optimizing Treatment Selection
- (2021) Ronald C. Kessler et al. JAMA Psychiatry
- The Effectiveness of Repeated Intravenous Ketamine on Depressive Symptoms, Suicidal Ideation and Functional Disability in Adults with Major Depressive Disorder and Bipolar Disorder: Results from the Canadian Rapid Treatment Center of Excellence
- (2020) Roger S McIntyre et al. JOURNAL OF AFFECTIVE DISORDERS
- Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
- (2020) Dawn F Ionescu et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
- (2020) Anees Bahji et al. JOURNAL OF AFFECTIVE DISORDERS
- The clinical characterization of the adult patient with depression aimed at personalization of management
- (2020) Mario Maj et al. World Psychiatry
- Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression
- (2020) Paulo R. Shiroma et al. JOURNAL OF AFFECTIVE DISORDERS
- The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research
- (2020) Hartej Gill et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis
- (2020) Jiaqi Xiong et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
- (2019) Vanina Popova et al. AMERICAN JOURNAL OF PSYCHIATRY
- Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
- (2019) Maggie Fedgchin et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review
- (2019) Bing Cao et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression
- (2019) Ella J. Daly et al. JAMA Psychiatry
- Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study
- (2019) Qingqing Liu et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3
- (2019) Rachel Ochs-Ross et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression
- (2019) Weijian Liu et al. JOURNAL OF AFFECTIVE DISORDERS
- Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: Role of BDNF-TrkB signaling
- (2019) Yunfei Tan et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
- (2018) Carla M. Canuso et al. AMERICAN JOURNAL OF PSYCHIATRY
- Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review
- (2018) Yena Lee et al. JOURNAL OF AFFECTIVE DISORDERS
- Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness
- (2018) Rejish K Thomas et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression
- (2018) Joshua D. Rosenblat et al. JOURNAL OF AFFECTIVE DISORDERS
- DSM-5 Criteria and Depression Severity: Implications for Clinical Practice
- (2018) Julio C. Tolentino et al. Frontiers in Psychiatry
- Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials
- (2017) Elizabeth D. Ballard et al. JOURNAL OF AFFECTIVE DISORDERS
- Cognitive Impairment in Patients With Depression: Awareness, Assessment, and Management
- (2017) Larry Culpepper et al. JOURNAL OF CLINICAL PSYCHIATRY
- Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism
- (2017) Lily R. Aleksandrova et al. JOURNAL OF PSYCHIATRY & NEUROSCIENCE
- Toward an Evidence-Based, Operational Definition of Treatment-Resistant Depression
- (2017) Charles R. Conway et al. JAMA Psychiatry
- Suicide, Suicide Attempts, and Suicidal Ideation
- (2016) E. David Klonsky et al. Annual Review of Clinical Psychology
- Assessing anhedonia in depression: Potentials and pitfalls
- (2016) Sakina J. Rizvi et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Cognitive Deficits as a Mediator of Poor Occupational Function in Remitted Major Depressive Disorder Patients
- (2016) Young Sup Woo et al. Clinical Psychopharmacology and Neuroscience
- Controversies of the Effect of Ketamine on Cognition
- (2016) Melvyn W. B. Zhang et al. Frontiers in Psychiatry
- Treating to target in major depressive disorder: response to remission to functional recovery
- (2015) Roger S. McIntyre et al. CNS SPECTRUMS
- Neural correlates of change in major depressive disorder anhedonia following open-label ketamine
- (2015) Níall Lally et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Existing and Novel Biological Therapeutics in Suicide Prevention
- (2014) Joshua J. Griffiths et al. AMERICAN JOURNAL OF PREVENTIVE MEDICINE
- The motivation and pleasure dimension of negative symptoms: Neural substrates and behavioral outputs
- (2014) Ann M. Kring et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- COGNITIVE DEFICITS AND FUNCTIONAL OUTCOMES IN MAJOR DEPRESSIVE DISORDER: DETERMINANTS, SUBSTRATES, AND TREATMENT INTERVENTIONS
- (2013) Roger S. McIntyre et al. DEPRESSION AND ANXIETY
- Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
- (2013) Roger S. McIntyre et al. JOURNAL OF AFFECTIVE DISORDERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now